BiotechTube

DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allogeneic Haematopoietic Stem Cell Transplantation

Conditions

Allogeneic Haematopoietic Stem Cell Transplantation

Trial Timeline

Sep 1, 2003 → Oct 1, 2006

NCT ID
NCT00169728

About DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar

DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar is a phase 3 stage product being developed by Pfizer for Allogeneic Haematopoietic Stem Cell Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00169728. Target conditions include Allogeneic Haematopoietic Stem Cell Transplantation.

What happened to similar drugs?

0 of 1 similar drugs in Allogeneic Haematopoietic Stem Cell Transplantation were approved

Approved (0) Terminated (1) Active (0)
❌Valganciclovir + GanciclovirRochePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00169728Phase 3Completed

Competing Products

9 competing products in Allogeneic Haematopoietic Stem Cell Transplantation

See all competitors
ProductCompanyStageHype Score
ASP0113Astellas PharmaPhase 2
35
Valganciclovir + GanciclovirRochePhase 3
32
Blinatumomab in combination with donor lymphocyte infusionAmgenPhase 2
27
DenosumabAmgenPhase 2
35
Inotuzumab Ozogamicin + Vincristine Sulfate LiposomePfizerPhase 1/2
24
Genotropin (Recombinant Human Growth Hormone)PfizerPhase 1
21
immunosuppressionPfizerPhase 2
27
Mycophenolate MofetilHikma PharmaceuticalsPre-clinical
20
Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 PlaceboSeres TherapeuticsPhase 1
19